Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Tofacitinib, the first oral janus kinase inhibitor approved for adult ulcerative colitis
A single subcutaneous dose of tirzepatide 5 mg was well-tolerated by all treatment groups
Receptors & Channels
Risk of stomach ulcer is rare, and PPI therapy is to be continued until removal
According to the Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA), gastrointestinal disturbances occur in a significant proportion of patients, with nausea affecting up to 20% of users
:quality(70)/https://assets.iprofesional.com/assets/jpg/2025/12/608597.jpg)
US$ 19.98
US$ 27.66
US$ 27.68
US$ 21.99
